Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, doub...
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
About this item
Full title
Author / Creator
Gold, Ralf, Prof , Giovannoni, Gavin, Prof , Selmaj, Krzysztof, Prof , Havrdova, Eva, Prof , Montalban, Xavier, Prof , Radue, Ernst-Wilhelm, Prof , Stefoski, Dusan, MD , Robinson, Randy, PhD , Riester, Katherine, MPH , Rana, Jitesh, MD , Elkins, Jacob, MD , O'Neill, Gilmore, MRCPI , for the SELECT study investigators and SELECT study investigators
Publisher
Kidlington: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Daclizumab, a humanised monoclonal antibody, modulates interleukin-2 signalling by blocking the α subunit (CD25) of the interleukin-2 receptor. We assessed whether daclizumab high-yield process (HYP) would be effective when given as monotherapy for a 1 year treatment period in patients with relapsing-remitting multiple sclerosis....
Alternative Titles
Full title
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Authors, Artists and Contributors
Author / Creator
Giovannoni, Gavin, Prof
Selmaj, Krzysztof, Prof
Havrdova, Eva, Prof
Montalban, Xavier, Prof
Radue, Ernst-Wilhelm, Prof
Stefoski, Dusan, MD
Robinson, Randy, PhD
Riester, Katherine, MPH
Rana, Jitesh, MD
Elkins, Jacob, MD
O'Neill, Gilmore, MRCPI
for the SELECT study investigators
SELECT study investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1371271232
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1371271232
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(12)62190-4
